GeneDx Holdings Corp. (WGS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.82 per share a year ago.
GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing. The company's second-quarter performance exceeded expectations, driven by over 125% year-over-year growth in its whole exome and genome business, now 74% of total revenue. GeneDx reduced its quarterly cash burn significantly and anticipates profitability by 2025, with increasing reimbursement rates and expanding Medicaid coverage boosting revenue.
GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics
GeneDx is helping patients navigate through the "diagnostic odyssey" with DNA sequencing. The biotech stock is on its own odyssey.
How Much Upside is Left in GENEDX HOLDINGS (WGS)? Wall Street Analysts Think 40.34%
The consensus price target hints at a 40.3% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GeneDx Holdings Corp. (WGS) Q2 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies William Bonello - Craig Hallum Mark Massaro - BTIG Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Good day and thank you for standing by. Welcome to the GeneDx Second Quarter 2024 Earnings Conference Call.
GeneDx Holdings Corp. (WGS) Reports Q2 Loss, Tops Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $1.65 per share a year ago.
What Makes GeneDx Holdings Corp. (WGS) a Strong Momentum Stock: Buy Now?
Does GeneDx Holdings Corp. (WGS) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About GENEDX HOLDINGS (WGS) Rating Upgrade to Strong Buy
GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
GeneDx Holdings Corp. focuses on delivering precise medical diagnostic outcomes through its genomic expertise and rare disease dataset. Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are key revenue drivers, growing 96% in the first quarter. Increasing acceptance and coverage by major commercial payers and Medicaid for exome and genome testing.
